Eric Schone and Randy Brown Mathematica Policy Research

Slides:



Advertisements
Similar presentations
Exchange Goals, Options, and Considerations Rick Curtis, President Institute for Health Policy Solutions May 11, 2009.
Advertisements

Factors Affecting Physicians Medicare Service Volume: Beneficiaries Treated and Services per Beneficiary By Jack Hadley and Jim Reschovsky 2005 Academy.
Development and Evaluation of CMS-HCC Concurrent Risk Adjustment Models Presented by Eric Olmsted, Ph.D. Gregory Pope, M.S. John Kautter, Ph.D. RTI International.
PAYING FOR PERFORMANCE In PUBLIC HEALTH: Opportunities and Obstacles Glen P. Mays, Ph.D., M.P.H. Department of Health Policy and Administration UAMS College.
Presented by the Illinois Department of Insurance Andrew Boron, Director November 2012.
How Do Hospitals Respond To Price Changes? By LEEMORE S. DAFNY.
Comparator Selection in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Health Reform in Kansas Murphy Society University of Kansas School of Medicine October 25, 2012 Suzanne Schrandt, J.D. Kansas Health Institute 1.
1 Beyond RADV Does Your Plan’s Risk Adjustment Strategy Run Afoul of the False Claims Act February 13, 2012 Mary Inman Tim McCormack Phillips & Cohen LLP.
The Patient Protection & Affordable Care Act (ACA) implements broad, historic changes to U.S. health care Expanded access to health insurance and care.
Presented by the Illinois Department of Insurance Andrew Boron, Director SEPTEMBER 2012.
Health Insurance Decisions, Expectations, and Job Turnover Randall P. Ellis Boston University and UTS-CHERE Albert Ma Boston University.
Medicare Part C and the CMS- HCCs Gail Woytek, RHIA, CCS June 2, 2014.
Impact of Hospital Provider Payment Mechanism on Household Health Service Utilization in Vietnam (preliminary results) Sarah Bales Public Policy in Asia,
Risk Adjustment Data For Business Insight Health Care Service Corporation September 2012.
1 Benefits in Health Insurance: Calculating the Costs and Premiums Alliance for Health Reform October 10, 2008 John Bertko, FSA, MAAA.
RISK ADJUSTMENT CODING
Problems and Improvements for the Financing of the Massachusetts Duals Demonstration A Presentation to the Implementation Council March 15, 2013 BD Group.
1 Variation in Medicare Part D Prescription Drug Plan Benefits, 2006 Leslie M. Greenwald, Ph.D. Principal Scientist RTI, International.
Using Electronic Data to Assess Physician Quality and Efficiency: Promise and Perils Peter V. Lee Consumer-Purchaser Disclosure Project Invitational Working.
Health Insurance Chapter 45 Employee Benefit & Retirement Planning Copyright 2011, The National Underwriter Company1 What is it? The most widespread employee.
DataBrief: Did you know… DataBrief Series ● February 2013 ● No. 38 Medicare Spending for Beneficiaries with Severe Mental Illness and Substance Use Disorder.
Academy Health Annual Meeting, Orlando, June 2007 What Accounts for the Rise in Medicare Spending? Kenneth E. Thorpe, Ph.D. Robert W. Woodruff Professor.
Hospital Utilization by Fee-for-Service and Medicare Advantage Enrollees Lauren Hersch Nicholas University of Michigan September 15, 2009.
Oregon's Coordinated Care Organizations: First Year Expenditure and Utilization Authors: Neal Wallace, PhD, Peter Geissert, MPH 1, and K. John McConnell,
PACE: A Foundation for Serving People with Intellectual Disabilities? Peter Fitzgerald National PACE Association Alexandria, VA
Overcoming the Risk Adjustment Payment Challenge John G. Lovelace, President July 2010.
Risk Adjustment Chapter 6. 2 Medicare AAPCC: Adjusted Average Per Capita Costs Average Medicare Part A + Part B expenditures Average Medicare Part A +
Medicare Part C & D 2012 Plan Ratings SNP Leadership Forum October 28, 2011 Liz Goldstein, Ph.D. Centers for Medicare & Medicaid Services.
Speaker Biography.
Presenter Disclosures
Chapter 10 Coding for Medical Necessity.
Health Reform: What It Means to Our Community
Why pricing transparency?
Clinical Medical Assisting
Experiences with the Marketplace
Medicaid Per Capita Caps: What Do They Mean for Me?
Alternative Payment Models in the Quality Payment Program
Medicare and Medicaid Week 3.
Presentation Developed for the Academy of Managed Care Pharmacy
A Framework for Paying for Social Determinants of Health
Group 7 Hospital Readmission Predictive Analytics
Lessons from Massachusetts for Health Insurance Exchanges
Risk adjustment in Medicare Advantage
DY6 Core Component & Sustainability Reporting
Dual eligible beneficiaries and care coordination
Spending Our Wealth on Health
Total U.S. prescription drug spending, in $ billions:
Medicare Risk Adjustment Update
IMPROVING OUTCOMES IN FEE FOR SERVICE MEDICARE
The Third National Medicare Congress David B. Snow, Jr.
Lindy Hinman Avalere Health LLC
Changes to HCC Criteria for Auto Approval
Next steps in oncology payment reform
Provider Peer Grouping: Project Overview
Theory, Results and Implementation
MRA Member Summary, Open Conditions & Clinical Inference
MEDICAID AND MMA ADMINISTRATIVE CHALLENGES: SPECIAL NEEDS PLANS
MEDICARE: RISKS & OPPORTUNITIES for 2019
Optum’s Role in Mycare Ohio
Produced with support from The SCAN Foundation
A View from Washington, DC
Presented by: John Kautter, Ph.D. Gregory Pope, M.S.
Discussion Topics History of Private Plans in Medicare
Jan Berger, M.D., M.J. Senior Vice President Chief Medical Officer
Bridges to Excellence: Recognizing High-Quality Care
Medicare Advantage 101: A Primer
The ACA’s Medicaid expansion: Fiscal bane or boon to states?
Delivering Care at Home for Medicare Advantage Enrollees
Policy Implications for Rural Healthcare
Presentation transcript:

Risk Adjustment: What Is the Current State of the Art and How Can it Be Improved? Eric Schone and Randy Brown Mathematica Policy Research October 11, 2013

Acknowledgments This review was performed with the support of the Robert Wood Johnson Foundation through its Synthesis Project

Purpose of Our Synthesis Summarize state of the art of risk adjustment Identify remaining shortcomings Suggest possible solutions

Uses of Risk Adjustment Minimize health plans’ opportunities to profit through favorable selection Ensure plans have adequate resources to provide for high-risk members Adjust quality measures for differences in case mix severity Key factor for ACA coverage expansion

Outline for Presentation Methods we used Findings Implications for policy

Methods Focus on health plan capitation Review of literature from past 20 years Evidence from Medicare Advantage, Other public and commercial risk adjustment users, Foreign health care systems with managed competition Includes scholarly literature, government and industry, interviews

Research Questions How does risk adjustment work and how can its effectiveness be measured? What models and data are used and how do they compare? What improvements have been tested and how well do they work? How vulnerable is risk adjustment to manipulation and how can it be avoided? How can we measure risk for the newly enrolled? How effective is risk adjustment in practice?

How can effectiveness be measured? Risk adjustment begins with risk assessment Percentage of variation explained by risk factors Mean absolute prediction error Predictive ratio for beneficiary groups Predictable profits

What models and data are used and how do they compare? Most models begin with diagnoses from encounter records Conditions can be inferred from prescription drugs Episodes of care include information about treatments Predictive power similar across models; short of health plans’ underwriting models

Some improvements involve more/better data Longer diagnostic history identifies more patients with chronic conditions Adding prescription drugs to encounter data is redundant Survey measures can identify health status and special needs Clinical data may make future models stronger

Other improvements involve changes to modeling methods Concurrent models fit the data better but do not eliminate predictable profits Including prior use or prior expenditures reduces predictable profits Truncation of costs reduces influence of unpredictable events

How vulnerable is risk adjustment to manipulation and what can be done about it? “Coding creep” increases profits by recording more diagnoses CMS reduces all payments to compensate Adjustment based on treatment or concurrent diagnoses vulnerable to manipulation Gameable diagnoses, prescriptions, treatments may be excluded

How can risk be measured for the newly enrolled? New enrollee models underpredict for chronic conditions Group adjustment is based on the prevalence of conditions within a population Concurrent adjustment uses post-enrollment information

How effective is risk adjustment in practice? Broadens risk profile of covered population MA covered population has become more diverse Biased disenrollment Group with highest risk-adjusted costs most likely to disenroll Biased enrollment MA enrollees have lower pre-enrollment costs within risk adjustment categories Other programs with risk adjustment show similar results

Summary/Conclusions Much improved, but shortcomings remain Upcoding distorts payments Benefits are designed to attract healthier people Best bets for improving accuracy: Truncating high-cost cases Including prior-year costs as predictor

Suggestion 1: Better Data Add concurrent diagnoses for select conditions to prospective adjuster Use diagnosis data from 2 prior years Add survey measures of frailty for subsets Include lab data to reflect severity Challenges: data cost, gaming

Suggestion 2: Include Number of Non-preventable Prior Hospitalizations in Adjuster Reflects effects of some prior costs Doesn’t reduce reward to plans from reducing costs Challenge: coding

Suggestion 3: Reduce the Returns to Gaming Compare risk adjuster to best possible predictor plans could use Replace universal reduction for upcoding with plan-specific penalties Challenge: devising proper incentives

Suggestion 4: Incentivize Retention of High- Risk Patients Reward plans that profit less from disenrollment Truncate costs for extreme outliers and provide reinsurance to cover liability Challenges: plans’ objections; cost of reinsurance; no incentive for extreme cases